drugset

drugset / Trial / NCT05704244

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05704244 ↗

Phase 3 Active not recruiting 25 enrolled Ferring Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.

Timeline

Start: 2022-12-21
Primary completion: 2029-11-30
Completion: 2029-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nadofaragene Firadenovec	Unknown	75 ml	Other

Indications